Evidence map›Paper›PMID 36450378›Full record

ArticleJournal for immunotherapy of cancer2022

Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis.

Wen Gao, Lingxiang Wu, Shidai Jin, Jun Li, Xinyin Liu, Jiali Xu, Wei Zhang, Qixing Gong, Chunxiao Sun, Wei Wang and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Wen Gao *Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Lingxiang Wu *Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, Jiangsu, China.
Shidai Jin *Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Jun Li *Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Xinyin LiuDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Jiali XuDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Wei ZhangDepartment of Radiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Qixing GongDepartment of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Chunxiao SunDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Wei WangDepartment of Neurology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Zidun WangDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Yang W ShaoGeneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, Jiangsu, China.
Jiani C YinGeneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, Jiangsu, China.ORCID 0000-0002-9523-1930
Lu ShenGeneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, Jiangsu, China.
Liang ChenDepartment of Thoracic Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China wangqh@njmu.edu.cn rhguo@njmu.edu.cn clbright0909@njmu.edu.cn.
Qianghu WangJiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, Jiangsu, China wangqh@njmu.edu.cn rhguo@njmu.edu.cn clbright0909@njmu.edu.cn.
Renhua GuoDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China wangqh@njmu.edu.cn rhguo@njmu.edu.cn clbright0909@njmu.edu.cn.ORCID 0000-0003-4475-8617
Jiangsu Province Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanism(s) of immune checkpoint inhibitor (ICI)-induced myasthenia gravis (MG), an immune-related adverse event (irAE) that is fatal and limits subsequent ICI use, remain unexplored. Here, through comparative genomic analysis, we identified a pathogenic p.S467C germline variant in

Indexed as

Myasthenia GravisThymomaThymus NeoplasmsCarnitineHumansImmune Checkpoint InhibitorsSolute Carrier Family 22 Member 5CarnitineImmune Checkpoint InhibitorsSLC22A5 protein, humanSolute Carrier Family 22 Member 5ImmunotherapyLung Neoplasms

Identifiers

PMID36450378
PMCPMC9716945
OpenAlexW4310580617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.